Misoprostol
Детермінований перегляд YAML-сутності з джерельної бази. Клінічний авторитет лишається за вказаними source ID та статусом клінічного sign-off.
| ID | DRUG-MISOPROSTOL |
|---|---|
| Тип | Препарат |
| Синоніми | CytotecМізопростол |
| Статус | переглянуто 2026-05-18 | очікує клінічного підпису |
| Хвороби | Не вказано |
| Джерела | SRC-NCCN-BCELL-2025 |
Дані про препарат
| Клас | Synthetic prostaglandin E1 analog |
|---|---|
| Механізм дії | Synthetic prostaglandin E1 analog with gastric mucosal protective effects (mucus + bicarbonate secretion, decreased gastric acid via enterochromaffin-like cell inhibition) and uterotonic activity. In oncology / cancer-prevention context: investigated as endometrial protection in tamoxifen users (theoretical rationale — endometrial PGE pathways). Evidence base is limited and inconsistent; not guideline-recommended for routine tamoxifen-associated endometrial protection. Primary FDA indications are NSAID-induced peptic ulcer prophylaxis and (off-label) obstetric uses. |
| Типове дозування | NSAID ulcer prevention: 200 mcg PO QID with food and at bedtime (alternative: 200 mcg BID-TID for tolerability). Tamoxifen endometrial protection (off-label, research context only): 200 mcg PO regimens have been studied — NOT a guideline-supported use; clinician judgment + IRB if pursued. |
| Зареєстровано в Україні | True |
| Відшкодовується НСЗУ | False |
| Остання перевірка для України | 2026-05-18 |
Застереження
- Misoprostol can cause uterine rupture, abortion, premature birth, or birth defects — use in pregnancy can lead to pregnancy loss; women must have negative pregnancy test before initiation and use effective contraception
Нотатки
STUB — v0.2 prevention-workstream authoring; pending two-Clinical-Co-Lead signoff per CHARTER §6.1 dev-mode. PRIMARY indication is NSAID-induced peptic ulcer prevention. CONTROVERSIAL alternative-only use for tamoxifen-associated endometrial protection — NOT NCCN/ESMO recommended; small studies have not shown clear benefit. Engine should NOT auto- recommend; reserved as clinician-judgment alternative pending dedicated guideline. Strict pregnancy exclusion mandatory. Source cited (SRC-NCCN-BCELL-2025) is closest in-KB until dedicated peptic-ulcer- prevention or tamoxifen-endometrium sources land.
Де використовується
У YAML-корпусі не знайдено зворотних посилань.